Immunoregulation and anti-metalloproteinase bioactive injectable polysalicylate matrixgel for efficiently treating osteoarthritis

• Published in: Materials today bio 2022-06, Vol.15, p.100277-100277, Article 100277
• Main Authors: Jia, Xinlin, Ma, Junping, Chen, Xuzhuo, Li, Wentao, Zhou, Xianhao, Lei, Bo, Zhao, Xin, Mao, Yuanqing
• Format: Article
• Language: English
• Subjects: Bioactive materials; Full Length; Multifunctional hydrogel; Osteoarthritis; Tissue engineering
• ISSN: 2590-0064; 2590-0064
• DOI: 10.1016/j.mtbio.2022.100277

Current treatments of osteoarthritis, such as oral medication and intra-articular injections, only provided temporary relief from pain and achieved limited advance in inhibiting progression. The development of new treatments is hindered by the complicated and unclear pathological mechanisms. Oxidative stress and immune inflammation are believed to be the important factors in the induction and progression of osteoarthritis. Herein, this work presents a bioactive material strategy to treat osteoarthritis, based on the FPSOH matrixgel with robust anti-inflammatory activity through inhibiting the oxidative stress and nuclear factor kappa B signaling, preventing the metalloproteinase, as well as inducing M2 polarization of macrophage, thereby providing immune regulation of synovial macrophages and suppressing the progression of synovitis and osteoarthritis. In vivo experiments demonstrated that FPSOH hydrogel can prevent papain-induced osteoarthritis and its progression, and provide dual protection for cartilage and synovium, as compared with commercial sodium hyaluronate. Scheme 1. Schematic illustration of synthesis of FPSOH hydrogel and treatment of osteoarthritis. [Display omitted]